We are developing a portfolio of novel therapeutics targeting metabolic diseases. Substantial unmet needs persist in obesity, particularly in achieving sustained weight loss, as well as addressing the key underlying pathologies that impact cardiometabolic health outcomes. Alveus aims to address these critical issues, delivering meaningful improvements in patient outcomes. In addition to our lead program, we are advancing an amylin pipeline of highly differentiated small molecules, peptides, and novel formats across multiple indications.
Our lead program ALV-100 combines GIPR antagonism with GLP-1 receptor agonism – a novel approach validated by human genetics showing that GIPR loss-of-function variants are associated with lower BMI and improved cardiometabolic traits. This dual mechanism delivers weight loss with lean mass preservation while addressing counterregulatory metabolic mechanisms that drive weight regain. We anticipate entering Phase 3 trials in 2027.